Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.66 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280252 | 0.87 | CTNNB1 (0.52) | FOLH1HRH4CTNNB1TDP1MME | |
| SCHEMBL7280245 | 0.87 | CTNNB1 (0.52) | FOLH1HRH4CTNNB1TDP1MME | |
| SCHEMBL6677809 | 0.85 | CTNNB1 (0.63) | HRH4CTNNB1TDP1MMEACE | |
| SCHEMBL10521941 | 0.84 | SIGMAR1 (0.53) | FOLH1HRH4CTNNB1TDP1 | |
| SCHEMBL10521472 | 0.83 | SIGMAR1 (0.52) | FOLH1HRH4CTNNB1TDP1 | |
| SCHEMBL10521682 | 0.82 | SIGMAR1 (0.51) | FOLH1HRH4CTNNB1TDP1 | |
| SCHEMBL9556717 | 0.82 | CTNNB1 (0.48) | FOLH1HRH4CTNNB1TDP1MME | |
| SCHEMBL7353938 | 0.82 | CTNNB1 (0.48) | FOLH1HRH4CTNNB1TDP1MME | |
| SCHEMBL10521224 | 0.82 | CTNNB1 (0.55) | FOLH1HRH4CTNNB1TDP1MME | |
| SCHEMBL5057987 | 0.81 | FOLH1 (0.71) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992215-B2 | Thiol-based NAALADase inhibitors | GUILDFORD PHARMACEUTICALS INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC, | 2005-04-21 | — | — | US | claimed |
| WO-2002057222-A9 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2004-05-06 | — | — | WO | claimed |
| EP-1353903-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002057222-A2 | THIOL-BASED NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-07-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085503-A1 | Thiol-based NAALADase inhibitors | NAALAD2, GLUL, FOLH1 | FOLH1 3/4885HRH4 4044/4885CTNNB1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.